@article{f42c79f013694e51bbb1dff1cd460e3e,
title = "Post-acute COVID-19 outcomes including participant-reported long COVID: amubarvimab/romlusevimab versus placebo in the ACTIV-2 trial",
keywords = "COVID-19, Clinical trial, Long COVID, Monoclonal antibodies, Outpatient treatment, Post COVID conditions, Post-acute sequelae of SARS-CoV-2 infection (PASC)",
author = "{ACTIV-2/A5401 Study Team} and Evering, {Teresa H.} and Carlee Moser and Nikolaus Jilg and Justin Ritz and Wohl, {David A.} and Li, {Jonathan Z.} and David Margolis and Javan, {Arzhang Cyrus} and Eron, {Joseph J.} and Currier, {Judith S.} and Daar, {Eric S.} and Smith, {Davey M.} and Hughes, {Michael D.} and Chew, {Kara W.} and Kara Chew and Smith, {David (Davey)} and Eric Daar and David Wohl and Judith Currier and Joseph Eron and Michael Hughes and Mark Giganti and Lara Hosey and Jhoanna Roa and Nilam Patel and Kelly Colsh and Irene Rwakazina and Justine Beck and Scott Sieg and Jonathan Li and Courtney Fletcher and William Fischer and Ignacio, {Rachel Bender} and Sandra Cardoso and Katya Corado and Prasanna Jagannathan and Alan Perelson and Sandy Pillay and Cynthia Riviere and Upinder Singh and Babafemi Taiwo and Joan Gottesman and Matthew Newell and Susan Pedersen and Joan Dragavon and Cheryl Jennings and Brian Greenfelder and William Murtaugh and Jan Kosmyna and Jennifer Veltman",
note = "Publisher Copyright: {\textcopyright} 2024",
year = "2024",
month = sep,
doi = "10.1016/j.eclinm.2024.102787",
language = "English",
volume = "75",
journal = "EClinicalMedicine",
issn = "2589-5370",
}